Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD4 | P21917 | 3/20 | 0.67 |
| ▸ | HPGD | P15428 | 3/20 | 0.67 |
| ▸ | GAA | P10253 | 4/20 | 0.66 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.66 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.64 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.64 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.64 |
| ▸ | TSHR | P16473 | 2/20 | 0.63 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.61 |
| ▸ | POLB | P06746 | 2/20 | 0.58 |
| ▸ | LMNA | P02545 | 1/20 | 0.58 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.58 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.58 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.58 |
| ▸ | USP2 | O75604 | 1/20 | 0.58 |
| ▸ | MEN1 | O00255 | 1/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14585685 | 0.90 | GAA (0.78) | DRD4HPGDGAANPSR1ALDH1A1 | |
| SCHEMBL29831539 | 0.87 | PARP1 (0.66) | GAA | |
| SCHEMBL3394834 | 0.85 | DRD4 (0.84) | DRD4GAANPSR1ALDH1A1HSD17B10 | |
| SCHEMBL4631962 | 0.85 | GAA (0.71) | DRD4HPGDGAANPSR1ALDH1A1 | |
| SCHEMBL3394276 | 0.85 | ALDH1A1 (0.73) | DRD4HPGDGAANPSR1ALDH1A1 | |
| SCHEMBL4632074 | 0.85 | GAA (0.67) | DRD4HPGDGAANPSR1ALDH1A1 | |
| SCHEMBL22639886 | 0.84 | GAA (0.73) | DRD4HPGDGAANPSR1ALDH1A1 | |
| SCHEMBL3394617 | 0.82 | DRD4 (0.70) | DRD4HPGDGAANPSR1ALDH1A1 | |
| SCHEMBL28358324 | 0.82 | PIM1 (0.55) | DRD4HPGDALDH1A1HSD17B10KDM4E | |
| SCHEMBL29723991 | 0.82 | PIM1 (0.55) | DRD4HPGDALDH1A1HSD17B10KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11407719-B2 | Anti-inflammatory agents | RESVERLOGIX CORP. (CA) | 2022-08-09 | — | — | US | disclosed |
| US-20210361656-A1 | COMPOUNDS FOR THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASES | HEPALINK (HONG KONG) LIMITED (HK) | 2021-11-25 | — | — | US | disclosed |
| US-20210070716-A1 | ANTI-INFLAMMATORY AGENTS | HEPALINK (HONG KONG) LIMITED (HK) | 2021-03-11 | — | — | US | disclosed |
| US-20200352946-A1 | COMPOUNDS FOR THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASES | RESVERLOGIX CORP. | 2020-11-12 | — | — | US | disclosed |
| US-20180104245-A1 | COMPOUNDS FOR THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASES | HEPALINK (HONG KONG) LIMITED (HK) | 2018-04-19 | — | — | US | disclosed |
| US-20160346291-A1 | COMPOSITIONS AND THERAPEUTIC METHODS FOR ACCELERATED PLAQUE REGRESSION | RESVERLOGIX CORP (CA) | 2016-12-01 | — | — | US | disclosed |
| US-20160106750-A1 | COMPOUNDS FOR THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASES | RESVERLOGIX CORP. (CA) | 2016-04-21 | — | — | US | disclosed |
| US-9199990-B2 | Compounds for the prevention and treatment of cardiovascular diseases | RESVERLOGIX CORP. (CA) | 2015-12-01 | — | — | US | disclosed |
| US-20150072955-A1 | COMPOUNDS FOR THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASES | RESVERLOGIX CORP. (US) | 2015-03-12 | — | — | US | disclosed |
| US-8889698-B2 | Compounds for the prevention and treatment of cardiovascular diseases | RESVERLOGIX CORP. (CA) | 2014-11-18 | — | — | US | disclosed |
| US-20130281397-A1 | TREATMENT OF DISEASES BY EPIGENETIC REGULATION | RVX THERAPEUTICS INC. (CA) | 2013-10-24 | — | — | US | disclosed |
| WO-2013156869-A1 | TREATMENT OF DISEASES BY EPIGENETIC REGULATION | RVX THERAPEUTICS INC. (CA) | 2013-10-24 | — | — | WO | disclosed |
| US-20120015905-A1 | COMPOUNDS FOR THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASES | RESVERLOGIX CORP. | 2012-01-19 | — | — | US | disclosed |
| US-8053440-B2 | Compounds for the prevention and treatment of cardiovascular diseases | Resverlogix Corporation (CA) | 2011-11-08 | — | — | US | disclosed |
| US-20080188467-A1 | To regulate the expression of apolipoprotein A-I; atherosclerosis; improved pharmacological properties; 3-(4-hydroxy-3,5-dimethylphenyl)-6,8-dimethoxyisoquinolin-1(2H)-one; to reduce cholesterol levels; agonists | HEPALINK (HONG KONG) LIMITED (HK) | 2008-08-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180104245-A1 | COMPOUNDS FOR THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASES | APOB, HDLBP, FABP3 | DRD4 4444/4885HPGD 522/4885GAA 477/4885 |
| US-11407719-B2 | Anti-inflammatory agents | VCAM1, ICAM1, IL6 | DRD4 2663/4885HPGD 1083/4885GAA 3104/4885 |
| US-20130281397-A1 | TREATMENT OF DISEASES BY EPIGENETIC REGULATION | BRD4, BMI1, BRPF3 | DRD4 4744/4885HPGD 3517/4885GAA 4457/4885 |
| US-20160346291-A1 | COMPOSITIONS AND THERAPEUTIC METHODS FOR ACCELERATED PLAQUE REGRESSION | PCSK9, TGFB1, HMGCR | DRD4 3924/4885HPGD 4094/4885GAA 307/4885 |
| US-20210070716-A1 | ANTI-INFLAMMATORY AGENTS | VCAM1, ICAM1, IL6 | DRD4 2663/4885HPGD 1083/4885GAA 3104/4885 |
| US-20210361656-A1 | COMPOUNDS FOR THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASES | APOB, HDLBP, FABP3 | DRD4 4444/4885HPGD 522/4885GAA 477/4885 |
| US-20120015905-A1 | COMPOUNDS FOR THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASES | APOB, HDLBP, FABP3 | DRD4 4444/4885HPGD 522/4885GAA 477/4885 |
| US-20200352946-A1 | COMPOUNDS FOR THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASES | APOB, HDLBP, FABP3 | DRD4 4444/4885HPGD 522/4885GAA 477/4885 |
| US-20160106750-A1 | COMPOUNDS FOR THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASES | APOB, HDLBP, FABP3 | DRD4 4444/4885HPGD 522/4885GAA 477/4885 |
| US-20150072955-A1 | COMPOUNDS FOR THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASES | APOB, HDLBP, FABP3 | DRD4 4444/4885HPGD 522/4885GAA 477/4885 |
| US-20080188467-A1 | To regulate the expression of apolipoprotein A-I; atherosclerosis; improved pharmacological properties; 3-(4-hydroxy-3,5-dimethylphenyl)-6,8-dimethoxyisoquinolin-1(2H)-one; to reduce cholesterol levels; agonists | APOB, LDLR, APOL1 | DRD4 1728/4885HPGD 1135/4885GAA 2827/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.